Clinical and epidemiological profile of Indian COVID-19 patients from Jaipur: a descriptive study


  • Sunil Mahavar Department of Medicine, Sawai ManSingh Medical College & Hospital, Jaipur, India.
  • Princy Tyagi Department of Medicine, Sawai ManSingh Medical College & Hospital, Jaipur, India.
  • Abhishek Agrawal | Department of Medicine, Sawai ManSingh Medical College & Hospital, Jaipur, India.
  • Sudhir Bhandari Department of Medicine, Sawai ManSingh Medical College & Hospital, Jaipur, India.
  • Subrata Banerjee Department of Medicine, Sawai ManSingh Medical College & Hospital, Jaipur, India.
  • Raman Sharma Department of Medicine, Sawai ManSingh Medical College & Hospital, Jaipur, India.
  • Prakash Keshwani Department of Medicine, Sawai ManSingh Medical College & Hospital, Jaipur, India.


We analyzed the data of 102 confirmed patients with novel Coronavirus 2 infection (COVID-19) during the early period of nationwide lockdown announced in India after the declaration of pandemic. We analyzed epidemiological, clinical characteristics and outcome of hospitalization in 102 patients with positive results for novel corona virus (SARS-CoV-2) RNA testing which were traced on the basis of history of travel, contact with a confirmed COVID-19 case, resident of hotspot areas or presence of symptoms, thus providing an accurate estimate of the proportion of asymptomatic cases in the initial population. Of 102 patients enrolled in the study, 83.3% (85/102) were asymptomatic and 16.67% (17/102) were symptomatic. Seventy-seven (75.49%) were males and 24.50% (25/102) were females. Eighteen (17.6%) patients had associated comorbidities, the most prevalent of which were diabetes mellitus 10.8% (11/102), hypertension 7.8% (8/102), chronic obstructive pulmonary disease (COPD) in 3.92% (4/102), chronic kidney Disease (CKD) 0.98% (1/102), coronary artery Disease (CAD) 0.98% (1/102) and cerebro-vascular disease (CVD) 0.98% (1/102). The clinical spectrum among symptomatic COVID-19 patients varied from dry cough and fever to respiratory failure and multi-organ failure. Twelve (11.76%) patients were kept in intensive care unit (ICU). Ninety-nine (97.05%) patients recovered while three (2.94%) died during hospital stay. With majority of COVID-19 cases in India being asymptomatic, changes in biochemical and inflammatory profile were small and insignificant in asymptomatic patients when compared to symptomatic patients. Elevated NLR, lymphopenia, age and presence of comorbidities were associated with increased severity and poor outcome.



PlumX Metrics


Download data is not yet available.


WHO. Pneumonia of unknown cause China. Emergencies, preparedness, response, disease outbreak news. World Health

Organization. 2020. Accessed: 8 May 2020. Available from:

Centers for Disease Control and Prevention. 2019 Novel Coronavirus, Wuhan, China. CDC. Accessed: 27 January 2020. Available from:

WHO. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. World Health Organization. 2020. Accessed: 4 May 2020. Available from:

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536-44. DOI:

WHO. Coronavirus pandemic. World Health Organization. 2020. Accessed: 25 July 2020. Available from:

Government of India [Internet]. #IndiaFightsCorona COVID-19. 2020. Accessed: 25 July 2020. Available from:

Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. J Infect 2020;80:e1-13. DOI:

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13. DOI:

Huang C,Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. DOI:

Kolifarhood G, Aghaali M, Mozafar Saadati H, et al. Epidemiological and clinical aspects of covid-19; a narrative review. Arch Acad Emerg Med 2020;8:e41.

Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732-9. DOI:

Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person

transmission: a study of a family cluster. Lancet 2020;395:514-23. DOI:

Ministry of Health and Family Welfare, Government of India. Guidelines on the clinical management of COVID-19. Accessed: 8 May 2020. Available from:

Şimşek yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020;50:611-9. DOI:

Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-

cases on board the Diamond Princess Cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020;25:2000180. DOI:

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239-42. DOI:

Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5. DOI:

Shi H, Han X, Jiang N et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20:425-34. DOI:

Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110-8. DOI:

Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin

in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 2020;34:101663. DOI:

Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787-99. DOI:

Baden LR, Rubin EJ. Covid-19 - The search for effective therapy. N Engl J Med 2020;382:1851-2. DOI:

European Centre for Disease Prevention and Control. Guidance for discharge and ending isolation in the context of widespread

community transmission of COVID-19, 8 April 2020. Stockholm: ECDC; 2020. Available from:


Pneumology - Original Articles
COVID-19, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), asymptomatic, clinical characteristic, India
  • Abstract views: 75

  • PDF: 39
How to Cite
Mahavar, Sunil, Princy Tyagi, Abhishek Agrawal, Sudhir Bhandari, Subrata Banerjee, Raman Sharma, and Prakash Keshwani. 2021. “Clinical and Epidemiological Profile of Indian COVID-19 Patients from Jaipur: A Descriptive Study”. Monaldi Archives for Chest Disease 91 (2).